Crinetics Pharmaceuticals' (CRNX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $60.00 price target on the stock. A number of other equities analysts also recently weighed in on the company. JMP Securities reiterated a market […]

Related Keywords

Stephenf Betz ,Robertw Baird ,Piper Sandler ,Marc Wilson ,Analyst Recommendations For Crinetics Pharmaceuticals ,Alps Advisors Inc ,Crinetics Pharmaceuticals Company Profile ,News Ratings For Crinetics Pharmaceuticals Daily ,Crinetics Pharmaceuticals Price Performance ,Hennion Walsh Asset Management Inc ,Comerica Bank ,Securities Exchange Commission ,Crinetics Pharmaceuticals ,Citigroup ,Cantor Fitzgerald ,Crinetics Pharmaceuticals Inc ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Walsh Asset Management ,Crinetics Pharmaceuticals Daily ,